Groundbreaking HIV Prevention Medication
Generic versions of a groundbreaking injectable HIV prevention medication should be available in more than 100 countries by 2027 for $40 a year.
Availability and Affordability
The two organizations have closed separate agreements with Indian pharmaceutical companies to produce cheaper generic versions of Lenacapavir, a twice annual injection.
Efficacy of Lenacapavir
Lenacapavir reduces the risk of HIV transmission by more than 99.9 percent for countries with low and medium income.
Details of the Agreement
Details of the agreements were provided by Unitaid Executive Director Philippe Duneton.
Impact on Low and Medium Income Countries
The availability of generic versions of Lenacapavir is expected to have a significant impact on the prevention of HIV transmission in low and medium income countries.
